Literature DB >> 16025126

The transcriptional repressor Nab1 is a specific regulator of pathological cardiac hypertrophy.

Monika Buitrago1, Kristina Lorenz, Alexander H Maass, Silke Oberdorf-Maass, Ursula Keller, Eva M Schmitteckert, Yuri Ivashchenko, Martin J Lohse, Stefan Engelhardt.   

Abstract

Hypertrophy represents the major physiological response of the heart to adapt to chronically enhanced workload, but is also crucial in the development of heart failure. Although we know of numerous inducers of cardiac hypertrophy, little is known about mechanisms that limit cardiac hypertrophy. Here, we describe the transcriptional repressor NAB1 as an endogenous regulator of cardiac growth. We identified NAB1 as being upregulated in both mouse and human heart failure. Nab1 is highly expressed in mammalian cardiac myocytes and it inhibited cardiomyocyte hypertrophy through repression of its targets, transcription factor Egr. Transgenic mice with cardiac-specific overexpression of Nab1 showed that Nab1 is a potent inhibitor of cardiac growth in response to pathological stimuli in vivo. Nab1 overexpression suppressed adrenergically induced and pressure overload-induced hypertrophy, whereas physiological growth during development and in response to exercise was not affected. These findings implicate the Nab1-Egr1 axis as a crucial regulator of pathological cardiac growth.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16025126     DOI: 10.1038/nm1272

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  38 in total

1.  Adrenergic stress reveals septal hypertrophy and proteasome impairment in heterozygous Mybpc3-targeted knock-in mice.

Authors:  Saskia Schlossarek; Friederike Schuermann; Birgit Geertz; Giulia Mearini; Thomas Eschenhagen; Lucie Carrier
Journal:  J Muscle Res Cell Motil       Date:  2011-11-11       Impact factor: 2.698

2.  FGF23 induces left ventricular hypertrophy.

Authors:  Christian Faul; Ansel P Amaral; Behzad Oskouei; Ming-Chang Hu; Alexis Sloan; Tamara Isakova; Orlando M Gutiérrez; Robier Aguillon-Prada; Joy Lincoln; Joshua M Hare; Peter Mundel; Azorides Morales; Julia Scialla; Michael Fischer; Elsayed Z Soliman; Jing Chen; Alan S Go; Sylvia E Rosas; Lisa Nessel; Raymond R Townsend; Harold I Feldman; Martin St John Sutton; Akinlolu Ojo; Crystal Gadegbeku; Giovana Seno Di Marco; Stefan Reuter; Dominik Kentrup; Klaus Tiemann; Marcus Brand; Joseph A Hill; Orson W Moe; Makoto Kuro-O; John W Kusek; Martin G Keane; Myles Wolf
Journal:  J Clin Invest       Date:  2011-10-10       Impact factor: 14.808

Review 3.  Re-employment of developmental transcription factors in adult heart disease.

Authors:  Toru Oka; Jian Xu; Jeffery D Molkentin
Journal:  Semin Cell Dev Biol       Date:  2006-11-24       Impact factor: 7.727

4.  Real-time optical recording of beta1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol.

Authors:  Francesca Rochais; Jean-Pierre Vilardaga; Viacheslav O Nikolaev; Moritz Bünemann; Martin J Lohse; Stefan Engelhardt
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

5.  Cardiomyocyte proliferation prevents failure in pressure overload but not volume overload.

Authors:  Karl Toischer; Wuqiang Zhu; Mark Hünlich; Belal A Mohamed; Sara Khadjeh; Sean P Reuter; Katrin Schäfer; Deepak Ramanujam; Stefan Engelhardt; Loren J Field; Gerd Hasenfuss
Journal:  J Clin Invest       Date:  2017-10-30       Impact factor: 14.808

Review 6.  Recent insights into cardiac hypertrophy and left ventricular remodeling.

Authors:  Risto Kerkela; Thomas Force
Journal:  Curr Heart Fail Rep       Date:  2006-04

7.  Interference with ERK(Thr188) phosphorylation impairs pathological but not physiological cardiac hypertrophy.

Authors:  Catharina Ruppert; Katharina Deiss; Sebastian Herrmann; Marie Vidal; Mehmet Oezkur; Armin Gorski; Frank Weidemann; Martin J Lohse; Kristina Lorenz
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-15       Impact factor: 11.205

8.  Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure.

Authors:  Sharad Rastogi; Victor G Sharov; Sudhish Mishra; Ramesh C Gupta; Brent Blackburn; Luiz Belardinelli; William C Stanley; Hani N Sabbah
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-09-26       Impact factor: 4.733

9.  Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome.

Authors:  Xonia Carvajal-Vergara; Ana Sevilla; Sunita L D'Souza; Yen-Sin Ang; Christoph Schaniel; Dung-Fang Lee; Lei Yang; Aaron D Kaplan; Eric D Adler; Roye Rozov; Yongchao Ge; Ninette Cohen; Lisa J Edelmann; Betty Chang; Avinash Waghray; Jie Su; Sherly Pardo; Klaske D Lichtenbelt; Marco Tartaglia; Bruce D Gelb; Ihor R Lemischka
Journal:  Nature       Date:  2010-06-10       Impact factor: 49.962

10.  PKA, Rap1, ERK1/2, and p90RSK mediate PGE2 and EP4 signaling in neonatal ventricular myocytes.

Authors:  Quan He; Pamela Harding; Margot C LaPointe
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-10-30       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.